Post Resch Tallon Group Inc. Syndax Pharmaceuticals Inc Transaction History
Post Resch Tallon Group Inc.
- $113 Billion
- Q3 2025
A detailed history of Post Resch Tallon Group Inc. transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Post Resch Tallon Group Inc. holds 25,800 shares of SNDX stock, worth $428,796. This represents 0.35% of its overall portfolio holdings.
Number of Shares
25,800Holding current value
$428,796% of portfolio
0.35%Shares
1 transactions
Others Institutions Holding SNDX
# of Institutions
254Shares Held
99.9MCall Options Held
1.41MPut Options Held
737K-
Kynam Capital Management, LP Princeton, NJ8.52MShares$142 Million11.08% of portfolio
-
Black Rock Inc. New York, NY7.91MShares$131 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY5.49MShares$91.2 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.14MShares$85.4 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.26MShares$70.7 Million0.13% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $940M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...